查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2003036

伴侶動物疫苗市場：依動物類型、疫苗類型、給藥途徑及通路分類－2026-2032年全球市場預測

Companion Animal Vaccine Market by Animal Type, Vaccine Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，伴侶動物疫苗市場價值將達到 53.9 億美元，到 2026 年將成長至 58.5 億美元，到 2032 年將達到 95.4 億美元，複合年成長率為 8.48%。

主要市場統計數據
基準年 2025 53.9億美元
預計年份：2026年 58.5億美元
預測年份：2032年 95.4億美元
複合年成長率 (%) 8.48%

全面介紹不斷發展的伴侶動物疫苗領域，探討科學創新、飼主期望和臨床實踐變化之間的交匯點。

伴侶動物疫苗的現況正處於科學進展、飼主期望變化和臨床實踐發展三者交會的階段。現代相關人員身處在一個預防醫學理念和治療方法創新共同塑造犬貓疫苗接種策略的環境，這影響著診所的工作流程和供應鏈動態。獸醫專業人員正日益將診斷篩檢、個人化疫苗通訊協定和基於風險的建議融入日常診療，這促使生產商和經銷商重新評估產品系列和傳播策略。

詳細概述了重塑伴侶動物疫苗的研發、交付和部署的關鍵技術、行為和臨床變化。

伴侶動物疫苗領域正經歷一場變革，其驅動力包括技術創新、消費者行為的改變以及監管和臨床模式的演變。疫苗平台，特別是mRNA和重組技術的進步，正在開闢新的可能性，例如靶向免疫策略、更短的研發週期以及能夠應對新出現的疾病威脅的高度適應性生產過程。這些科學進步正在重新定義產品藍圖，並促使現有製造商重新評估其研發重點和策略夥伴關係關係。

對 2025 年美國關稅措施對伴侶動物疫苗的供應鏈、生產決策和通路經濟的累積影響進行全面分析。

2025年，美國實施的關稅措施進一步增加了伴侶動物疫苗生態系統中製造商、經銷商和臨床終端用戶的複雜性。這些關稅影響了進口原料、成品疫苗和專用設備的成本結構，從而改變了供應鏈決策，並促使企業重新評估製造地。一些相關人員加快了近岸外包的步伐，並相關人員供應商組合多元化，以降低貿易相關的成本波動風險。另一些利害關係人則尋求合約避險策略，以確保獲得關鍵投入品。

可操作的細分情報揭示了動物類型、疫苗平台、給藥途徑和分銷管道如何相互交織，從而塑造產品類型和商業化策略。

細分市場分析揭示了不同動物類型、疫苗平台、給藥途徑和分銷管道的需求促進因素、臨床偏好和分銷管道趨勢的差異。就動物類型而言，貓和狗在流行病學和寵物飼養方面表現出不同的特徵，這些特徵會影響疫苗接種的優先順序、接種計劃和飼主的諮詢。犬類疫苗接種策略通常專注於針對戶外暴露和社交互動量身定做的核心疫苗和生活方式疫苗，而貓的疫苗接種通訊協定則優先考慮與室內/室外生活條件和多貓家庭動態相關的疾病風險。

從策略區域角度深入了解不同的管理體制、獸醫基礎設施和飼主行為如何導致世界各地市場出現不同的因應方式。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的臨床實務規範、法律規範和商業性模式均有顯著影響。在美洲，獸醫基礎設施和飼主參與模式支援多元化的分銷管道，而強大的獸醫醫院網路和數位技術的廣泛應用則促進了預防保健解決方案的分銷和零售。相較之下，歐洲、中東和非洲的法規環境和經濟狀況環境各不相同，需要高度本地化的監管策略和靈活的分銷模式，以適應成熟的獸醫市場和新興細分市場。

詳細的競爭格局和生態系統評估揭示了成熟企業、生物技術創新者和服務供應商如何塑造其採用和商業化策略。

伴侶動物疫苗領域的競爭動態呈現出成熟企業、專業生技公司和新興創新者並存的態勢。成熟製造商繼續利用其廣泛的業務基礎、與獸醫專業人士的長期合作關係以及涵蓋傳統疫苗平台的豐富產品系列。這些優勢支撐著規模化生產、可靠的分銷管道和深厚的臨床洞察力，從而能夠與獸醫網路和機構採購商建立並維持長期的合作關係。

為領導者提供清晰且優先的策略建議，重點在於平台多元化、供應鏈彈性、管道最佳化和臨床證據的產生。

產業領導者應圍繞四個相互關聯的行動調整其策略重點：投資平台多元化、增強供應鏈韌性、最佳化通路策略以及深化臨床合作。透過優先採用組合策略，平衡成熟的去活化疫苗和減毒活病毒疫苗與對mRNA、重組疫苗、次單元和類毒素技術的投資，企業可以同時滿足當前的臨床需求並應對未來的疾病威脅。此外，選擇可擴展的生產合作夥伴並考慮區域生產能力，可以減輕貿易中斷的影響，並支持快速的市場反應。

採用穩健的混合調查方法，結合對關鍵相關人員的訪談、整合第二手資料和交叉檢驗，確保獲得可操作且可靠的見解。

本報告的調查方法結合了質性訪談、二手文獻整合以及嚴格的交叉檢驗，以確保分析的平衡性和可靠性。主要見解是透過對獸醫、行業高管、研發負責人和分銷專家的結構化訪談獲得的，這些訪談提供了關於臨床應用、產品偏好和物流挑戰的真實觀點。這些定性資訊與二級資訊來源（包括監管指南、同行評審的科學文獻和公開的行業報告）相結合，從而能夠對技術和市場趨勢進行背景分析。

簡明扼要地總結了決定伴侶動物疫苗領域策略成果的關鍵技術、商業性和區域挑戰。

本執行摘要整合了影響伴侶動物疫苗的關鍵趨勢，重點闡述了科學創新、不斷變化的飼主期望、不斷演變的分銷管道以及地緣政治供應因素之間的相互作用。 mRNA疫苗和重組疫苗等技術的成熟，以及去活化疫苗、減毒活病毒疫苗、次單位疫苗和類毒素疫苗平台的持續應用，為研發人員提供了多種選擇，以滿足尚未滿足的需求並提高安全性。隨著給藥途徑偏好和分銷管道趨勢的同步變化，需要製定協調一致的策略，以確保臨床應用和飼主的依從性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：伴侶動物疫苗市場：依動物類型分類

  • 貓
  • 狗

第9章：伴侶動物疫苗市場：依疫苗類型分類

  • 失活
    • 分裂細胞
    • 全細胞
  • 減毒活病毒疫苗
  • mRNA
  • 重組
  • 次單元
  • 類毒素

第10章：伴侶動物疫苗市場：依給藥途徑分類

  • 黏膜
    • 鼻內
    • 口服
  • 腸外
    • 肌肉內部
    • 皮下

第11章 伴侶動物疫苗市場：依通路分類

  • 線上
    • 網路藥房
    • 製造商網站
  • 藥局
  • 動物診所
  • 動物醫院

第12章：伴侶動物疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：伴侶動物疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 伴侶動物疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國伴侶動物疫苗市場

第16章：中國伴侶動物疫苗市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • SAN Group BIoTech Germany GmbH
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-957C47F94D1F

The Companion Animal Vaccine Market was valued at USD 5.39 billion in 2025 and is projected to grow to USD 5.85 billion in 2026, with a CAGR of 8.48%, reaching USD 9.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.39 billion
Estimated Year [2026] USD 5.85 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 8.48%

Comprehensive introduction to the evolving companion animal vaccine environment where scientific innovation converges with owner expectations and clinical practice shifts

The companion animal vaccine landscape sits at an intersection of scientific advancement, shifting owner expectations, and evolving clinical practice. Contemporary stakeholders operate in an environment where both preventive care philosophy and therapeutic innovation shape vaccination strategies for cats and dogs, influencing clinic workflows and supply chain dynamics. Veterinary professionals increasingly integrate diagnostic screening, individualized vaccine protocols, and risk-based recommendations into routine care, prompting manufacturers and distributors to reassess product portfolios and communication tactics.

As consumer awareness of animal health grows, pet owners demand clearer evidence of vaccine safety and benefit, while digital channels accelerate access to educational content and purchasing options. Concurrently, research breakthroughs in platform technologies such as mRNA and recombinant systems are expanding the range of antigen targets and enabling improved immunogenicity and manufacturing efficiencies. These developments prompt manufacturers to balance legacy product support for inactivated and live attenuated vaccines with investment in next-generation modalities.

In addition, the route of administration and the distribution landscape influence both product design and commercial strategy. Mucosal vaccines administered nasally or orally present different acceptance profiles compared with parenteral intramuscular or subcutaneous injections, and online channels including e-pharmacies and manufacturer websites are transforming procurement behaviors. Taken together, these dynamics require an integrated approach to product development, regulatory strategy, and market engagement that aligns scientific opportunity with practical adoption pathways.

In-depth overview of the major technological, behavioral, and clinical shifts reshaping how companion animal vaccines are developed, delivered, and adopted

The companion animal vaccine sector is undergoing transformative shifts driven by technological innovation, changing consumer behaviors, and evolving regulatory and clinical paradigms. Advances in vaccine platforms, notably mRNA and recombinant technologies, are opening new possibilities for targeted immunization strategies, shorter development cycles, and adaptable manufacturing processes capable of responding to emergent disease threats. These scientific advancements are redefining product roadmaps and prompting incumbent manufacturers to re-evaluate R&D priorities and strategic partnerships.

Simultaneously, the role of digital engagement continues to expand. Pet owners now access veterinary information, make purchasing decisions, and seek telehealth consultations through online portals, influencing the prominence of e-pharmacies and manufacturer direct-sales channels. This shift compels stakeholders to develop integrated omni-channel strategies that combine educational outreach, transparent efficacy and safety data, and streamlined purchasing experiences to build trust and foster adherence to vaccination schedules.

Moreover, changing societal views on preventive healthcare for pets and rising expectations around convenience and individualized care are reshaping clinical practice. Veterinarians are increasingly employing risk-based vaccination protocols, leveraging diagnostic tools to tailor immunization plans for individual animals, and prioritizing vaccine types and routes that optimize compliance and minimize adverse events. Together, these factors constitute a structural shift in how vaccines are developed, distributed, and recommended, creating both challenges and opportunities for innovators and service providers across the value chain.

Comprehensive analysis of the cumulative repercussions of United States tariff measures in 2025 on supply chains, manufacturing decisions, and commercial channel economics for companion vaccines

In 2025, tariff measures implemented by the United States introduced an added layer of complexity for manufacturers, distributors, and clinical end users within the companion animal vaccine ecosystem. Tariffs influence cost structures across imported raw materials, finished vaccines, and specialized equipment, thereby altering supply chain decisions and encouraging re-evaluation of manufacturing footprints. Some stakeholders accelerated nearshoring and diversified supplier portfolios to mitigate exposure to trade-related cost volatility, while others sought contractual hedges that preserved access to critical inputs.

These trade policy adjustments also impacted commercial planning and pricing strategies across distribution channels. Veterinary hospitals and clinics that source vaccines internationally reevaluated procurement cycles and supplier terms to maintain predictable inventory levels. Online pharmacies and manufacturer direct channels responded by adjusting their sourcing mixes and logistics arrangements to sustain delivery timelines and service levels to pet owners. In parallel, regulatory compliance and customs administration became more salient considerations during product launches and cross-border distribution discussions.

Furthermore, the tariff-driven recalibration of supply chains prompted renewed attention to domestic manufacturing capabilities and public-private partnerships that support biomanufacturing resilience. Investors and strategic leaders began to weigh the benefits of building local capacity against the capital requirements and timeframes involved, prioritizing technologies that offer flexible production scales. Collectively, these adjustments reflect a broader industry imperative to enhance supply chain robustness, reduce single-source dependencies, and align commercial models with an environment of elevated trade uncertainty.

Actionable segmentation intelligence illuminating how animal type, vaccine platform, administration route, and distribution channel intersect to shape product and commercialization strategies

Segmentation insights reveal how demand drivers, clinical preferences, and channel behaviors vary across animal type, vaccine platform, administration route, and distribution pathways. When considering animal type, cats and dogs display distinct epidemiological and husbandry profiles that shape vaccine prioritization, dosing schedules, and owner counseling. Vaccination strategies for dogs often emphasize core and lifestyle vaccines aligned with outdoor exposure and social interactions, whereas feline protocols prioritize disease risks aligned with indoor/outdoor status and multi-cat household dynamics.

Diving into vaccine type, inactivated platforms and live attenuated vaccines remain well-established for a variety of indications, with inactivated formulations further differentiated into split cell and whole cell options that influence immunogenicity and reactogenicity considerations. Emerging modalities such as mRNA and recombinant vaccines are creating opportunities to target diseases with greater precision and to design antigen constructs that optimize immune response while potentially reducing adverse events. Subunit and toxoid vaccines continue to play critical roles for specific pathogens where targeted antigen presentation or neutralization of toxins is essential.

Route of administration is another vital differentiator, with mucosal options delivered nasally or orally offering non-invasive alternatives to parenteral intramuscular and subcutaneous injections and enabling unique immunological profiles. Distribution channel dynamics further influence access and adoption; online channels comprised of e-pharmacies and manufacturer websites, along with more traditional outlets such as pharmacies, veterinary clinics, and veterinary hospitals, present differing customer journeys and regulatory considerations. Understanding how these segmentation axes intersect is essential for designing product portfolios, clinical guidance, and channel strategies that align with stakeholder expectations and operational realities.

Strategic regional insights into how diverse regulatory regimes, veterinary infrastructures, and owner behaviors drive differentiated approaches across global markets

Regional dynamics significantly influence clinical practice norms, regulatory frameworks, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, veterinary care infrastructure and owner engagement models support diverse distribution channels, with strong clinic networks and growing digital adoption that enhances outreach and retailing of preventive healthcare solutions. In contrast, Europe, Middle East & Africa exhibits a mosaic of regulatory environments and economic contexts, requiring highly localized regulatory strategies and flexible distribution models that accommodate both advanced veterinary markets and emerging segments.

Asia-Pacific presents a mix of rapid innovation adoption and variable access to veterinary services, where urbanization and rising pet ownership in key markets drive demand for modern vaccine technologies while logistical considerations and regional supply chains influence product availability. Across all regions, cultural attitudes toward companion animals, public health priorities, and veterinary training standards shape how vaccination protocols are recommended and accepted. These regional nuances necessitate tailored market entry strategies, localized clinical evidence packages, and targeted communication campaigns that resonate with veterinarians and pet owners alike.

Ultimately, effective regional planning integrates epidemiological insight with pragmatic supply and distribution models, regulatory navigation, and stakeholder engagement to ensure that vaccine innovations reach the right markets with appropriate supporting materials and service models.

Deep competitive and ecosystem assessment revealing how incumbents, biotech innovators, and service providers shape adoption and commercialization strategies

Competitive dynamics in the companion animal vaccine sector reflect a blend of established incumbents, specialist biotech firms, and emerging innovators. Established manufacturers continue to leverage broad commercial footprints, long-standing relationships with veterinary professionals, and extensive product portfolios that span traditional vaccine platforms. These capabilities support scale, distribution reliability, and deep clinical familiarity, enabling sustained engagement with veterinary networks and institutional buyers.

At the same time, specialist companies and biotech entrants focus on platform innovation, targeting high-value indications and leveraging technologies such as recombinant antigens and mRNA constructs to differentiate on efficacy, safety, and speed-to-market. These players often pursue strategic collaborations with contract manufacturing organizations and academic groups to accelerate development while optimizing capital allocation. Partnerships between large-scale manufacturers and nimble innovators are increasingly common, facilitating combination strategies that pair commercial reach with scientific novelty.

Service providers across the value chain, including contract manufacturers, diagnostic firms, and digital health platforms, play a pivotal role in enabling product development, quality assurance, and customer engagement. Their capabilities in scalable manufacturing, cold chain logistics, and data-driven marketing help translate scientific advances into clinically adopted products. Overall, the competitive landscape favors organizations that combine scientific differentiation, manufacturing resilience, and a deep understanding of veterinary practice dynamics to achieve sustained adoption among clinicians and pet owners.

Clear and prioritized strategic recommendations for leaders focused on platform diversification, supply resilience, channel optimization, and clinical evidence generation

Industry leaders should align strategic priorities around four interconnected actions: invest in platform diversification, fortify supply chain resilience, optimize channel strategies, and deepen clinical engagement. Prioritizing a portfolio approach that balances established inactivated and live attenuated products with investments in mRNA, recombinant, subunit, and toxoid technologies will allow organizations to respond to both current clinical needs and future disease threats. Concurrently, selecting scalable manufacturing partners and considering regional production capabilities can reduce exposure to trade disruptions and support faster market responsiveness.

Equally important is the refinement of distribution strategies to reflect evolving purchaser behaviors. Strengthening digital channels such as e-pharmacies and manufacturer direct-sales platforms should be complemented by reinforced relationships with pharmacies, veterinary clinics, and hospitals to ensure clinical adoption and continuity of care. In addition, tailoring messaging to emphasize route-of-administration benefits, whether mucosal or parenteral, and providing robust clinical evidence will improve veterinarian confidence and owner acceptance.

Finally, leaders should invest in targeted clinical education and real-world evidence generation that supports differentiated product positioning and informs risk-based vaccination protocols. Executing these recommendations requires cross-functional coordination across R&D, regulatory, commercial, and supply chain teams to translate strategic intent into measurable adoption outcomes.

Robust mixed-method methodology combining primary stakeholder interviews, secondary evidence synthesis, and cross-validation to ensure actionable and credible insights

The research methodology underpinning this report combines primary qualitative interviews, secondary literature synthesis, and rigorous cross-validation to ensure balanced analysis and credibility. Primary insights were obtained through structured interviews with veterinary practitioners, senior industry executives, R&D leaders, and distribution specialists, providing grounded perspectives on clinical adoption, product preferences, and logistical challenges. These qualitative inputs were synthesized with secondary sources that include regulatory guidance, peer-reviewed scientific literature, and publicly available industry reports to contextualize technological and market trends.

To enhance reliability, findings were cross-validated across multiple stakeholder groups and geographic contexts, with particular attention to differences in clinical practice patterns between developed and emerging veterinary markets. The approach emphasizes transparency in assumptions, clear documentation of data provenance, and adherence to ethical standards in primary research engagements. Analytical methods include trend mapping, technology readiness assessment, and channel pathway analysis to illuminate commercialization implications and strategic options for stakeholders.

This methodology ensures that insights are not only descriptive but also actionable, offering decision-makers a robust foundation to evaluate innovation opportunities, distribution choices, and investment priorities within the companion animal vaccine landscape.

Concise conclusion synthesizing technological, commercial, and regional imperatives that determine strategic outcomes in the companion animal vaccine sector

This executive summary synthesizes the essential dynamics shaping companion animal vaccines, underscoring the interplay of scientific innovation, changing owner expectations, distribution evolution, and geopolitical supply considerations. The maturation of technologies such as mRNA and recombinant vaccines, coupled with enduring roles for inactivated, live attenuated, subunit, and toxoid platforms, provides a broad palette for developers to address unmet clinical needs and improve safety profiles. Parallel shifts in route-of-administration preferences and distribution channel behaviors require coordinated strategies to ensure clinical adoption and owner adherence.

Moreover, regional differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific emphasize the importance of localized regulatory navigation and culturally attuned engagement. The cumulative impact of trade policy adjustments highlighted the need for supply chain agility and potential investments in regional manufacturing capabilities. Competitive success will favor organizations that can blend scientific differentiation with commercial scale, resilient operations, and deep partnerships across veterinary networks and digital channels.

In conclusion, stakeholders that proactively align R&D, manufacturing, and commercial strategies while investing in clinical evidence and channel integration will be best positioned to translate innovation into improved animal health outcomes and sustainable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Vaccine Market, by Animal Type

  • 8.1. Cats
  • 8.2. Dogs

9. Companion Animal Vaccine Market, by Vaccine Type

  • 9.1. Inactivated
    • 9.1.1. Split Cell
    • 9.1.2. Whole Cell
  • 9.2. Live Attenuated
  • 9.3. mRNA
  • 9.4. Recombinant
  • 9.5. Subunit
  • 9.6. Toxoid

10. Companion Animal Vaccine Market, by Route Of Administration

  • 10.1. Mucosal
    • 10.1.1. Nasal
    • 10.1.2. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Subcutaneous

11. Companion Animal Vaccine Market, by Distribution Channel

  • 11.1. Online
    • 11.1.1. E Pharmacies
    • 11.1.2. Manufacturer Websites
  • 11.2. Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Companion Animal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Companion Animal Vaccine Market

16. China Companion Animal Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Arko Corp.
  • 17.6. Bimeda Biologicals Inc
  • 17.7. Biogenesis Bago S.A.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Ceva Sante Animale
  • 17.10. Dechra Pharmaceuticals PLC
  • 17.11. Elanco Animal Health Incorporated
  • 17.12. Endovac Animal Health
  • 17.13. Hester Biosciences Limited
  • 17.14. Hipra S.A.
  • 17.15. Huvepharma, Inc.
  • 17.16. Indian Immunologicals Ltd.
  • 17.17. Kemin Industries, Inc.
  • 17.18. Merck & Co., Inc.
  • 17.19. Neogen Corporation
  • 17.20. Pfizer, Inc.
  • 17.21. Phibro Animal Health Corporation
  • 17.22. SAN Group Biotech Germany GmbH
  • 17.23. Seppic by Air Liquide Healthcare
  • 17.24. SK Bioscience
  • 17.25. Vaxxinova
  • 17.26. Virbac S.A.
  • 17.27. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 190. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)